We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $163M
1-Year Est. Return 240.43%
This Fund
S&P 500
This Quarter Est. Return
+30.38%
1 Year Est. Return
+240.43%
3 Year Est. Return
+409.28%
5 Year Est. Return
+142.09%
10 Year Est. Return
+4,071.98%
AUM
$163M
AUM Growth
+$21.2M
Cap. Flow
-$11.1M
Cap. Flow %
-6.85%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
1
Monte Rosa Therapeutics
GLUE
$1.03B
$77M 47.34%
3,180,780
– –
IPSC icon
2
Century Therapeutics
IPSC
$337M
$29.8M 18.33%
12,166,109
– –
JBIO
3
Jade Biosciences
JBIO
$1.08B
$22M 13.55%
991,783
-534,037
-35% -$11.1M
LENZ
4
LENZ Therapeutics
LENZ
$128M
$15.1M 9.28%
2,656,888
– –
CTNM
5
Contineum Therapeutics
CTNM
$509M
$8.89M 5.47%
542,628
– –
CRSP icon
6
CRISPR Therapeutics
CRSP
$5.47B
$8.12M 4.99%
148,831
– –
SKYE icon
7
Skye Bioscience
SKYE
$7.79M
$1.39M 0.86%
250,963
– –
TPST icon
8
Tempest Therapeutics
TPST
$16M
$299K 0.18%
269,772
– –

Similar funds

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
GF
Gimbal Financial Carmel, Indiana $163M AUM
ACM
Arrington Capital Management Miami, Florida $163M AUM
KFS
Krane Financial Solutions Calabasas, California $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
GCM
Generation Capital Management Pittsford, New York $163M AUM 42.22% 1-Year Est. Return

Versant Venture Management's Q2 2026 Portfolio in Review

As of Q2 2026, Versant Venture Management held 8 positions worth $163M, up 15% from $141M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $11.1M in Q2 2026, reducing 1 holding. Its largest reduction was Jade Biosciences, cutting an estimated $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management's biggest Q2 2026 reduction was Jade Biosciences, cutting an estimated $11.1M.
  • Versant Venture Management's ten largest holdings make up 100% of its $163M portfolio in Q2 2026.
  • Versant Venture Management opened 0 new positions and closed 0 in Q2 2026.
  • Versant Venture Management's portfolio value rose 15% quarter-over-quarter to $163M.

Based on Versant Venture Management's 13F filing for Q2 2026, filed 12 Aug 2026.